A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in Southern ...
Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of DexCom in a research note issued to ...
Investor's Business Daily on MSN2d
Why Dexcom Is On A Six-Day Losing Spree — But This Analyst Isn't WorriedDexcom stock plunged to a four-month low Monday after the FDA issued a warning letter tied to inspections of two facilities ...
Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...
DexCom projects 2025 revenue of $4.6 billion ... and a second-half launch of a 15-day G7 product. Gross profit margins for 2025 are expected to improve by at least 200 basis points, reaching ...
DexCom specializes in continuous glucose monitoring systems, primarily focusing on individuals managing diabetes. Its innovative CGM systems, like the G6 and the newer G7, offer real-time glucose ...
Zacks.com on MSN2d
Reasons to Hold TNDM Stock in Your Portfolio for NowTandem Diabetes Care, Inc.’s TNDM fourth-quarter 2024 performance was driven by its impressive range of new products. The company’s impressive strategic initiatives provide a favorable opportunity for ...
In a regulatory filing, DexCom (DXCM) disclosed that on March 4, the company received a warning letter from the U.S. FDA following inspections ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback